1. Progressive Fibrosing Interstitial Lung Diseases – Addressing the Challenges Concept of Progressive Fibrosing ILDs With Examples

2. Program Key Points

3. Program Agenda

4. ILDs Classification

5. Classification of IIPs According to Disease Behavior: ATS/ERS Updated

6. Progressive Fibrosing ILDs as a Subgroup of the ILDs

7. Characteristics of Progressive Fibrosing ILDs

8. How Do These Patients Look?

9. Progressive Fibrosing ILD with UIP Pattern

10. Progressive Fibrosing ILD with iNSIP and a Non-UIP Pattern

11. Signs of Fibrosing Disease at HRCT

12. Challenges Encountered During Patient Assessment/Diagnosis

13. Diseases Encompassed by Progressive Fibrosing ILD

14. How Is Progression Defined in Progressive Fibrosing ILDs

15. Conclusions

16. Morbidity and Mortality of Progressive Fibrosing ILDs: Value of Biomarkers, Present and Future

17. Introduction

18. Impact of Progressive Fibrosing ILDs on Patients

19. Comorbidities Associated With Progressive Fibrosis

20. Comorbidities Associated With CTD

21. Consequences of Comorbidities

22. Impact on Mortality

23. Characteristics of Good Biomarkers

24. Biomarkers Associated With a Risk of Progression

25. Serum Biomarkers Associated With a Decline of Lung Function and Reduced Survival

26. Biomarkers Associated With a Prognosis on IPF

27. Conclusions

28. Current Treatment Options and Unmet Needs

29. Introduction

30. Options in Non-IPF ILDs (vs IPF)

31. Most Common Agents Used in IPF

32. Most Common Immunomodulatory Agents Used in Non-IPF ILDs

33. Limitations of Current Treatments

34. Characteristics of Progression

35. Progressive Fibrosing ILDs as a Subgroup of the ILDs

36. Pathogenic Mechanisms Common to IPF and Other Progressive Fibrotic Lung Diseases

37. Conclusions

38. Ongoing Clinical Trials of Potential Therapies for Non-IPF Progressive Fibrosing ILDs Including the Use of Antifibrotic Therapy

39. Introduction

40. Progressive Fibrosing ILDs as a Subgroup of the ILDs

41. What Is Progressive Fibrosing ILD?

42. Rationale for the Use of Antifibrotic Therapies in Progressive Fibrosing ILDs

43. Rationale for the Use of Antifibrotic Therapies in Progressive Fibrosing ILDs (cont)

44. Key Data With Pirfenidone in IPF

45. Key Data With Nintedanib in IPF

46. Ongoing Clinical Trials in Progressive Fibrosing ILDs

47. Pirfenidone Key Inclusion Criteria

48. Pirfenidone Key Inclusion Criteria (cont)

49. INBUILD Nintedanib Key Inclusion Criteria

50. INBUILD Nintedanib Key Inclusion Criteria (cont)

51. New Treatments Under Development

52. Abbreviations

53. Abbreviations (cont)